European Society of Medical Oncology (ESMO) 2021 Congress Sep 16, 2021 Supporting Materials Phase (Ph) 2 Study of Zanidatamab + Chemotherapy in First-line (1L) HER2-expressing Gastroesophageal Adenocarcinoma (GEA) 762.5 KB
Phase (Ph) 2 Study of Zanidatamab + Chemotherapy in First-line (1L) HER2-expressing Gastroesophageal Adenocarcinoma (GEA) 762.5 KB